Striking A Balance: Weighing the Benefits and Risks of Treatment With Direct Oral Anticoagulants in Individuals With Nonvalvular Atrial Fibrillation or Venous Thromboembolism
1.00 hr(s) | CME
Specialty: Nonvalvular Atrial Fibrillation
Therapeutic Area(s): Cardiology , Hematology , Oncology , Pulmonology
Release Date: April 21, 2021
Expiration Date: April 20, 2022
Location: Internet Activity Enduring
In this activity, a series of simulations will allow participants to assess patients with NVAF and VTE to better identify barriers to treatment, evaluate the risk of thrombotic events vs risks of bleeding, and choose the right DOAC or other options in anticoagulation therapy for each patient.